ArticleBMC nephrology2025
End-of-life healthcare utilisation and costs of older patients on kidney replacement therapy - analysis of Dutch health insurance claims data.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients on kidney replacement therapy (KRT) face high symptom and treatment burden, especially at end of life. Yet insights into end-of-life healthcare utilisation and costs remain limited. We aimed to describe healthcare utilisation and costs during the last year of life across KRT modalities.
methodsWe used Dutch health insurance claims data to identify incident and prevalent patients aged ≥ 65 years, treated with KRT during the year preceding death, and who deceased between June 2016 and December 2021. Healthcare utilisation and costs in the last year of life were analysed for different KRT modalities and compared with controls without kidney disease-related claims, with controls being matched on sex, age, socio-economic status, and year of death.
resultsWe identified 7279 patients on KRT (4614 haemodialysis [HD] patients, 766 peritoneal dialysis [PD] patients and 1899 kidney transplant [KTx] recipients) and 14,558 controls. During their last year of life, 85% of patients on KRT experienced ≥ 1 hospital admission, with 27% requiring intensive care - representing to 2.6- and 3.5-fold higher proportions than in their controls, with minimal variation across KRT modalities. Similar differences were observed for emergency department visits, outpatient visits, and long-term care use. Healthcare utilisation significantly increased in the last three months preceding death, more markedly among patients on KRT than controls (p < 0.001). Average healthcare costs were 5.9, 5.5 and 3.0 times higher for patients on HD (€117,520), PD (€108.294), and KTx recipients (€59,489), respectively, compared to controls (€19,820). KRT-unrelated costs, encompassing 40% to 74% of total costs, were 2.2 to 2.6 times higher in patients on KRT compared to controls, with specialist hospital care costs being three times higher.
conclusionIn the last year of life, healthcare utilisation is higher for patients on KRT compared to controls, with a further increase towards end-of-life, along with higher KRT-unrelated costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.